CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo
Authors' conclusion
CytoSorb hemoperfusion effectively attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo, whereas it does not affect long-term immune function.
Study context
- Population
- Healthy male volunteers (age 18–35) challenged intravenously with lipopolysaccharide (LPS) on day 0 and day 7
- Participants
- 24 volunteers
- Comparison
- CytoSorb hemoperfusion during first LPS challenge vs no intervention
- Primary endpoint
- Plasma cytokine concentrations
- Follow-up
- First LPS challenge
Methodological detailsrepeated human experimental endotoxemia model
- Repeated human experimental endotoxemia model
Primary result
As reported in the abstract
Plasma cytokine levels, CytoSorb vs control, first LPS challenge · first LPS challenge (day 0)
Tumor necrosis factor (TNF) lower with CytoSorb (p < 0.0001)
- 58%
IL-6 lower with CytoSorb (p = 0.003)
- 71%
IL-8 lower with CytoSorb (p = 0.02)
- 48%
IL-10 lower with CytoSorb (p = 0.03)
- 26%
Further findings
Cytokine responses during second LPS challenge (endotoxin tolerance) · day 7
- No differences in cytokine responses
Original publication
CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →